Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Safety and early efficacy results of a phase Ib study of nivolumab plus trastuzumab with S-1/capecitabine plus oxaliplatin for HER2-positive advanced gastric cancer (Ni-HIGH study).
Presenter
Daisuke Takahari, MD, PhD
The Cancer Institute Hospital of the Japanese Foundation for Cancer Research
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
UMIN000034222
DOI
10.1200/JCO.2022.40.4_suppl.276
Abstract #
276
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Speaker: Tara O. Henderson, MD, MPH
Videos & Slides
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of nivolumab and CapeOX in patients with previously untreated FGFR2-positive, PD-L1-positive advanced gastric cancer: A single-arm, multicenter, phase 2 study NIVOFGFR2.
Speaker: Ilya Tsimafeyeu, MD
Videos & Slides
2024 ASCO Gastrointestinal Cancers Symposium
A retrospective analysis of the efficacy and safety of capecitabine plus oxaliplatin (CapeOX) and docetaxel plus S-1 (DS) as adjuvant chemotherapy for pathological stage III (p stage III) gastric cancer (GC).
Speaker: Toru Imai, MD
Videos & Slides
2022 ASCO Gastrointestinal Cancers Symposium
Nivolumab (NIVO) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy, safety, and subgroup analyses from CheckMate 649.
Speaker: Kohei Shitara, MD